New research highlights significant insurance-driven hurdles, increasing second-line uptake of Fabhalta (Novartis), and strong physician interest in pipeline therapies including zaltenibart (Omeros), ...

Pharma is pretty much throwing everything it has at COVID-19 and US rare disease firm Alexion has joined the fray, testing its Ultomiris in a subset of severely ill patients. A biologic medicine ...

AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris – until now, that is. The drugmaker confirmed ...

Alexion to present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at EAN 2025: Cambridge, UK Monday, June 23, 2025, 13:00 Hrs [IST] ...

Biologics revolutionize generalized myasthenia gravis care with fast-acting, patient-friendly therapies and a robust global pipeline redefining outcomes. The gMG treatment era is shifting rapidly-from ...

Vor Bio is licensing global rights a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder ...

The European Commission ((EC)) approved AstraZeneca's (AZN) Ultomiris to treat a rare central nervous system disorder. Read more here ...

AstraZeneca (AZ) and CSPC Pharmaceuticals Group have entered into a partnership worth up to $5.3bn to develop therapies for chronic conditions. The strategic research collaboration will focus on the ...

When global asset teams come together in the early commercialisation phase – right through to phase 3 design and governance – they’re typically packed with highly experienced specialists, each ...